Connect with us

Government

German Government to Hold Hearings on Recreational Cannabis Reform

Published

on

The German government announced yesterday that hearings will start on Tuesday and last for the rest of June as it begins the formal process of recreational cannabis reform.

There is certainly something to be said about German cannabis reform that the rest of the world—and in particular, the U.S.—can learn from. The issue may have dragged excruciatingly slowly forward since 2017, but now that they have decided to actually do it, the government is moving forward quite fast to implement a new policy.

Last week, the government announced that ten new federal positions would be funded to oversee the new market. Two will be at BfArM, the medicines and medical devices agency where the current Cannabis Agency is located, and eight more will be directly under the Ministry of Health. The distinction is one of bureaucratic semantics as BfArM is an independent agency under the rubric of the health ministry. Yet this is Germany, land of bureaucratic hair splitting.

Yesterday, the Health Ministry also announced that it would start the first of five hearings today with the process lasting for the duration of June. More than 200 people are expected to take part—drawn from medical, legal, and business verticals, along with government officials and “international experts.”

The Ministry was told in a typically German and blunt fashion by the Bundestag budget committee last month that it was tasked with introduction of a bill that would be passable by the end of the year—or they would lose a million euros allocated for their PR budget.

The Impact of German Recreational Reform in Europe

While nothing is ever definite except death and taxes, it is highly likely that German recreational reform will pass by the end of this year. When the actual market starts is another question. Like Canada, or on a state level, Colorado and Washington State, sales could be delayed until the start of 2024. 

There are also other critical elements of legalization to be decided, such as decriminalization. Sales will be a large topic and range from how brick and mortar dispensaries will be set up to the ever-thorny issue of online sales. Clearing both previous convictions as well as pending legal cases is also a priority. There are about 200 criminal cases pending against legitimate CBD businesses, and over 185,000 against individuals, mostly for non-violent and personal cultivation and possession.

Beyond domestic impact—which also includes the creation of a regulatory structure for commercial cultivation, processing, packaging, and distribution beyond sales—there is another issue now front and center in this discussion and impacts the conversation across Europe. Namely where the richest country in the E.U. will source its recreational product—particularly until domestic cultivation is harvested. No matter how much new cultivation is initiated by all three medical bid winners, they will not be able to produce enough to supply the domestic market (nor should they be allowed to try). This also seems to indicate that feeder markets, including those cultivators now sourcing medical grade flower from countries including Portugal and Greece, are primed to step into the breach.

This in turn is also likely to drive further reform in most, if not all, other E.U. countries—especially those now on the brink of reform anyway. Portugal and Luxembourg have already announced progress on recreational reform since Germany announced an expedited schedule this spring. They are unlikely to be the only countries in Europe who will act. This is a valuable export crop not only for developing world countries, but many in Europe as well. Spain is one of them.

What Will Be the International Impact?

Beyond the immediate states of Europe, the impact of Germany going full Monty recreational will be massive. Its population is twice the size of Canada.

Apart from the domestic market and the inevitable topic of exports, it is also inevitable that political reform here will drive the issue in other places—starting with the U.S. (at minimum). 

If the Germans can do it, and within five years of federal reform of the medical kind (which also has not happened yet in the U.S.), there is little to hold this conversation back anywhere else.

What this also may well presage is further talks at the UN level, where reform has been punted for several years now. Removing cannabis from a Schedule I drug is now closer than it has been since before international prohibition which began to be implemented globally after WWI.

Quite ironically, the country which lost both of the global conflicts of the last century may well go down in history as the revolutionary force on the winning as well as the right side of history when it comes to cannabis.

Source: https://hightimes.com/news/german-government-to-hold-hearings-on-recreational-cannabis-reform/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News